ICER said there's no doubt Vertex's CF drug Trikafta provides substantial benefits to patients, but the company would need to drop the price at least 73% for it to be cost effective. (Vertex Pharma) ...
I was living on the precipice of end-stage disease when I enrolled in the clinical trial that resulted in the historically fast Food and Drug Administration approval for the game-changing cystic ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The expanded approval was based on clinical and/or in vitro data demonstrating responsiveness across 564 variants for Alyftrek and 521 variants for Trikafta. The label expansions were granted based on ...
Even amid political pressure from RFK Jr. and President Trump, as well as failed clinical data on VX-993, Vertex continues to strengthen its position in the cystic fibrosis market. Sales of its three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results